Delcath Reminds Shareholders that the Rights Offering Subscription Period Expires Wednesday, September 26, 2018
September 13, 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reminds its...
Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC to be Published in European Radiology
September 04, 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Announces Extension of Rights Offering Period to September 26, 2018
August 28, 2018 08:33 ET
|
Delcath Systems, Inc.
NEW YORK, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that...
Delcath Announces Acceptance of Abstract for Poster Presentation at CIRSE 2018
August 27, 2018 09:00 ET
|
Delcath Systems, Inc.
NEW YORK, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Delcath Announces 3rd Independent Safety Review of Randomized Trial Data for Metastatic Ocular Melanoma; Recommended Continuation with no Trial Modification
August 23, 2018 11:14 ET
|
Delcath Systems, Inc.
NEW YORK, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Delcath Announces Pending Expiration to Rights Offering Subscription Period
August 22, 2018 09:41 ET
|
Delcath Systems, Inc.
NEW YORK, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reminds its...
First Patient Enrolled in Delcath Amended Registration Trial in Metastatic Ocular Melanoma
August 21, 2018 08:52 ET
|
Delcath Systems, Inc.
NEW YORK, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Delcath Announces Beginning of Enrollment of Amended Metastatic Ocular Melanoma Registration Trial
August 20, 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Delcath Issues Letter to Stockholders
August 17, 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Aug. 17, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH) (“Delcath” or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic...
Delcath Announces Second Quarter Fiscal 2018 Financial Results
August 15, 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces...